Long-term clinical outcome was analysed in a series of 337 patients with early gastric cancer (EGC) at a median follow-up of 8 years. Tumours were classified according to the macroscopic and microscopic criteria proposed by the Japanese society of gastroenterological endoscopy (JSGE) and Lauren, respectively. Type of penetration (PEN) was classified according to Kodama. Overall survival rate was 92% at 5 years and 88% at 8 years and was significantly related to depth, type of penetration, lymph node status and tumour size. A significantly lower 5-year survival (p<0.05) was observed for patients with lymph node metastases and PEN A type EGC (55%) or for those with node-positive tumours and submucosal wall penetration (58%) than for the other pathologic subgroups. Therefore, these two subgroups should be considered as advanced gastric cancer patients from the prognostic point of view. Moreover, multivariate analysis by Cox regression model showed the degree of lymph node involvement and Kodama's type PEN A as the only independent prognostic factors.

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.5.4.945DOI Listing

Publication Analysis

Top Keywords

gastric cancer
12
early gastric
8
337 patients
8
type penetration
8
cancer province
4
province forlì
4
forlì follow-up
4
follow-up 337
4
patients high
4
high risk
4

Similar Publications

Background: As seen globally, there are up to sixfold differences in gastric cancer mortality by ethnicity in Aotearoa New Zealand, and H. pylori is the major modifiable risk factor. This study investigates whether current H.

View Article and Find Full Text PDF

RNA Modification and Digestive Tract Tumors: A Review.

Curr Med Chem

January 2025

Department of Infectious Diseases, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471000, Henan, China.

Gastrointestinal tumors, including colorectal and liver cancer, are among the most prevalent and lethal solid tumors. These malignancies are characterized by worsening prognoses and increasing incidence rates. Traditional therapeutic approaches often prove ineffective.

View Article and Find Full Text PDF

An Anticancer Bioactive Peptide Combined with Oxaliplatin Inhibited Gastric Cancer Cells and .

Curr Protein Pept Sci

January 2025

Key Laboratory of Medical Cell Biology in Inner Mongolia, Clinical Medical Research Center, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia,010050, China.

Background: Gastric cancer has become one of the major diseases threatening human health. This study aimed to investigate the mechanism of an anticancer bioactive peptide (ACBP) combined with oxaliplatin (OXA) on MKN-45, SGC7901, and NCI-N87 differentiated human gastric cancer cells and GES-1 immortalized human gastric mucosal epithelial cells. The therapeutic effect and action mechanism of short-term intermittent ACBP combined with OXA on nude mice with human gastric cancer were also investigated.

View Article and Find Full Text PDF

Esophagectomy for Cancer After One Anastomosis Gastric Bypass.

Ann Thorac Surg Short Rep

September 2023

Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota.

One anastomosis gastric bypass (OAGB) is growing in popularity, although it is potentially associated with biliary gastritis and gastroesophageal reflux esophagitis, with a potential rise in esophageal carcinoma. We describe the surgical management of a 53-year-old man with history of OAGB in whom biliary reflux and esophageal adenocarcinoma developed. We performed a minimally invasive Ivor Lewis esophagectomy, resected the sleeved stomach pouch, created a new conduit out of the remnant greater curve of the remnant stomach with blood supply from an intact gastroepiploic artery, and created an esophagogastric anastomosis.

View Article and Find Full Text PDF

Serological tests for needs local validation as the diagnostic accuracy may vary depending on the prevalence of . . This study examined the diagnostic performance of two ELISA, GastroPanel (GastroPanel ELISA; Biohit Oyj) and GENEDIA (GENEDIA .

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!